Definium Therapeutics Inc share price logo

Definium Therapeutics Inc Share Price

NASDAQ: DFTX

Small Cap

$17.78

+0.60

(+3.49%)

Live

as on

Definium Therapeutics Inc Stock Performance

as on March 4, 2026 at 6:06 am IST

  • Day's Low

    Day's High

    $16.55
    $17.95
    downward going graph

    6.92%

    Downside

    0.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Definium Therapeutics Inc share price movements today

Previous Close
$17.18
Open
$16.79
Volume
1.7M
Day's Low - High
$16.55 - $17.95

Definium Therapeutics Inc Historical Returns

1 Month Return
-4.02 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Definium Therapeutics Inc Stock Fundamentals & Key Indicators

Check Definium Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

-1.906

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-64.06%

Definium Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Definium Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
NA$1.7BNANA0.00%
BUY$126.2B133.18%32.4732.94%
BUY$44.2B125.24%142.888.45%
NA$35.1BNA621.555.37%
BUY$82.6B77.02%18.8331.41%

Definium Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Definium Therapeutics Inc Stock has decreased by -75% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-75% versus previous 30 day period

Definium Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Income
-24
-32
-32
-40
-45
EBITDA
-1
-34
-22
-40
-65
Interest Expense
0
0
0
2
1
Depreciation
-
-
-
-
-
Income Before Tax
-13
-34
-23
-42
-67
Income Tax Expense
-
-
-
-
-
Net Income
-13
-34
-23
-42
-67
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%

Definium Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
Gross Profit
-
-
-3
0
Operating Income
-93
-66
-93
-103
EBITDA
-91
-63
-92
-105
Interest Expense
0
1
0
2
Depreciation
2
3
3
0
Income Before Tax
-94
-56
-95
-108
Income Tax Expense
-1
-
-
-
Net Income
-93
-56
-95
-108
Net Profit Margin
0.00%
0.00%
0.00%
0.00%

Definium Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-23
-54
-5
-13
-34
-23
-42
-67
-50
Operating Cash Flow
-20
-16
-19
-17
-25
-29
-29
-29
-72
Investing Cash Flow
-
-
-
-
-
-162
-39
15
50
Financing Cash Flow
2
169
10
69
3
1
19
0
246
Change in Cash
-17
152
-9
52
-21
-190
-49
-13
-

Definium Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-1
0
-1
-33
-93
-56
-95
-108
-183
Operating Cash Flow
0
0
0
-23
-45
-50
-64
-79
-131
Investing Cash Flow
-3
0
0
-
0
-
-
-
-151
Financing Cash Flow
4
0
0
96
98
59
21
253
267
Change in Cash
0
0
0
73
53
8
-42
174
-15

Insights on Definium Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, DFTX stock has moved up by 43.9%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, DFTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, DFTX has outperformed top 5 stocks with highest market-cap in its industry

About Definium Therapeutics Inc

Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
OrganisationDefinium Therapeutics Inc
HeadquartersOne World Trade Center, New York, NY, United States, 10007
CEOMr. Robert Barrow
E-voting on sharesClick here to vote

Key Management of Definium Therapeutics Inc

Name

Title

Mr. Mark R. Sullivan J.D.

Chief Legal Officer & Corporate Secretary

Ms. Brandi L. Roberts CPA, M.B.A.

Chief Financial Officer

Mr. Peter Mack

Senior Vice President of Pharmaceutical Development & Operations

Ms. Gitanjali Jain Ogawa

VP & Head of Investor Relations

Ms. Stephanie Fagan M.S.

Chief Corporate Affairs Officer

Mr. Robert Barrow

CEO & Director

Dr. Daniel Rollings Karlin M.A., M.D.

Chief Medical Officer

Dr. Scott M. Freeman M.D.

Co-Founder & Clinical Advisor

Mr. Leonard Latchman

Co-Founder

Ms. Beth Calitri

Vice President of Corporate Communications

FAQs

What is Definium Therapeutics Inc share price today?

Definium Therapeutics Inc share price today is $17.78 as on . Definium Therapeutics Inc share today touched a day high of $17.95 and a low of $16.55.

What is the 52 week high and 52 week low for Definium Therapeutics Inc share?

Definium Therapeutics Inc share touched a 52 week high of $ on and a 52 week low of $ on . Definium Therapeutics Inc stock price today i.e. is trending at $17.78,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Definium Therapeutics Inc's market capitalisation today?

Definium Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Definium Therapeutics Inc Stock (DFTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Definium Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Definium Therapeutics Inc Shares that will get you 0.0844 shares as per Definium Therapeutics Inc share price of $17.78 per share as on March 4, 2026 at 12:36 am IST.

What is the minimum amount required to buy Definium Therapeutics Inc Stock (DFTX) from India?

Indian investors can start investing in Definium Therapeutics Inc (DFTX) shares with as little as ₹92.074 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹920.74 in Definium Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Definium Therapeutics Inc share’s latest price of $17.78 as on March 4, 2026 at 12:36 am IST, you will get 0.5624 shares of Definium Therapeutics Inc. Learn more about fractional shares .